The development and clinical use of trastuzumab (Herceptin).
about
ErbB2 degradation mediated by the co-chaperone protein CHIPOlive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells.Persistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transferIn vivo targeting of HER2-positive tumor using 2-helix affibody molecules.The multicompartmental p32/gClqR as a new target for antibody-based tumor targeting strategiesTargeted inhibition of kinases in cancer therapypH-sensitive degradable nanoparticles for highly efficient intracellular delivery of exogenous proteinFuture potential of thymidylate synthase inhibitors in cancer therapy.Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor.The Clinical Efficacy and Cardiotoxicity of Fixed-Dose Monthly Trastuzumab in HER2-Positive Breast Cancer: A Single Institutional Analysis.NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis.Proof of concept to clinical confirmation: evolving clinical trial designs for targeted agents.Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.Anti-CD 40 monoclonal antibody.Molecular imaging of insulin-like growth factor 1 receptor in cancer.Trastuzumab in the management of early and advanced stage breast cancer.Beyond structure, to survival: activation of Stat3 by cadherin engagement.Evaluation of PTEN loss and PIK3CA mutations and their correlation with efficacy of trastuzumab treatment in HER2-positive metastatic breast cancer: A retrospective study (KBC-SG 1001)Somatic variation and cancer: therapies lost in the mix.Blockade of a key region in the extracellular domain inhibits HER2 dimerization and signaling.Active targeting of HER2-positive breast cancer cells by Herceptin-functionalized organically modified silica nanoparticlesTemporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways.EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?Tailoring drug therapy based on genotype.Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes.Injectable supramolecular hydrogel from insulin-loaded triblock PCL-PEG-PCL copolymer and γ-cyclodextrin with sustained-release property.Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis.Real-time PCR quantification of c-erbB-2 gene is an alternative for FISH in the clinical management of breast carcinoma patients.Antibacterial and EGFR-tyrosine kinase inhibitory activities of polyhydroxylated xanthones from Garcinia succifolia.Reduction and temperature dual-responsive crosslinked polymersomes for targeted intracellular protein delivery
P2860
Q28208008-988AD526-A859-4D52-9F07-9948856891A8Q33284158-61641761-0F2F-4115-AA7C-B69472AC2C6FQ34005560-063AF4C1-B197-404C-B79E-9CD38EAAD0DDQ34231627-E2739ABC-599B-43D4-A9A3-BDD2AC6331A4Q34568373-13E6E1FC-69EF-4722-8352-048DAD8294F3Q34683348-E83F0401-105E-454C-8336-7DF958D8ADF6Q34987935-E6687986-A19D-4C11-A336-920C5302B9D0Q35011904-0ACFCFAD-EB67-4E48-BB1F-76A43DA88F8DQ35551142-A370384D-ED6C-4D50-AC71-3421C44B3078Q35948882-11DC24C0-CDC5-4688-9338-FB90E8B90545Q35971557-E27B66D0-7582-4CAE-8A3D-1FEE847073E9Q36021866-C032747F-B766-4D50-AABA-386A847A9AB8Q36139709-B6A4FB58-E82B-47AC-A8C8-D6FFAD2073A1Q36221538-9485C908-3CD3-49AD-B96B-37FA96134A50Q36337268-5516F3A4-CDA2-4B3F-940A-A2689264C6C0Q37290613-64E7A8C5-58FC-4B09-BF3C-070F77BD4BDFQ37638228-6CEABB88-92D1-4E4D-A04D-BF14634AB368Q37641066-E3CE42BB-5796-42B7-B88B-A717AEF5854AQ37885276-7F67FB6E-124A-494B-83BC-697E2C7BE1DDQ38885404-354E3318-58C0-4175-A3BC-861DEB9954DBQ39219446-60DC9C66-5442-48DC-9F55-EFAE6455D7CFQ39282042-1073E8CD-2FC0-4635-B6DD-01A70676C429Q39340502-5DBE4D42-F0B0-45E3-ABD4-200350A3591EQ39566450-E3F0BA1B-1206-4F02-97FA-4744F7F6C5B4Q39667920-12581144-9396-4D9F-919D-D727A6B8A3FDQ41987650-9A313D87-DAA2-43AD-B132-64F6AEBE08F9Q42374085-623E6AE4-9ACC-4A36-B78E-CF18BE5A8FE2Q54696645-7A204076-6C1D-4423-9495-220E43E81283Q55069634-537BD328-E319-4AB4-B601-FC0364C3E909Q57367160-D6894D0B-FD26-43BD-95B6-1EAD722C35AA
P2860
The development and clinical use of trastuzumab (Herceptin).
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The development and clinical use of trastuzumab (Herceptin).
@ast
The development and clinical use of trastuzumab (Herceptin).
@en
The development and clinical use of trastuzumab
@nl
type
label
The development and clinical use of trastuzumab (Herceptin).
@ast
The development and clinical use of trastuzumab (Herceptin).
@en
The development and clinical use of trastuzumab
@nl
prefLabel
The development and clinical use of trastuzumab (Herceptin).
@ast
The development and clinical use of trastuzumab (Herceptin).
@en
The development and clinical use of trastuzumab
@nl
P356
P1476
The development and clinical use of trastuzumab (Herceptin).
@en
P2093
P356
10.1677/ERC.0.0090075
P577
2002-06-01T00:00:00Z